CENTENE CORP

Centene Corporation operates as the nation's largest managed care company, primarily serving underserved populations through government-sponsored and subsidized healthcare programs. The company's core business model revolves around providing affordable and high-quality products to over 1 in 15 individuals across the United States, leveraging a local approach with community-based teams and a partnership mindset with providers, policymakers, and communities. Centene is recognized as the largest Medicaid and Marketplace insurer, as well as the largest stand-alone Medicare Prescription Drug Plan (PDP) provider, with its Medicare Advantage business also featuring a high concentration of Dual Eligible Special Needs Plan (D-SNP) members, aligning with its focus on complex, low-income populations. The company's strategy emphasizes improving health outcomes by addressing upstream drivers of health, such as food insecurity and housing instability, and utilizing data and insights to personalize care and enhance the overall healthcare system.

The company's operations are segmented into Medicaid, Medicare, Commercial, and Other. The Medicaid segment, which accounted for 57% of total external revenues in 2025, encompasses programs like Temporary Assistance for Needy Families (TANF), Medicaid Expansion, Aged, Blind or Disabled (ABD), Children's Health Insurance Program (CHIP), Long-Term Services and Supports (LTSS), Foster Care, and Medicare-Medicaid Plans (MMPs), though MMPs concluded on December 31, 2025, as CMS transitions to D-SNP-based integration. As of December 31, 2025, Centene served 12.5 million Medicaid members across 30 states, with contracts in Florida and New York individually contributing 10% or more of consolidated Medicaid premium revenues. The Medicare segment, representing 19% of total external revenues, includes Medicare Advantage, D-SNPs, Medicare Prescription Drug Plans (PDPs), and Medicare Supplement products. Under the Wellcare brand, Centene served 1.0 million Medicare Advantage members across 32 states and 8.1 million PDP members in 50 states and the District of Columbia as of December 31, 2025, making it the largest stand-alone PDP provider. The Commercial segment, contributing 21% of total external revenues, offers Health Insurance Marketplace products, individual and commercial group plans, Individual Coverage Health Reimbursement Arrangement (ICHRA) offerings, and other off-exchange individual products. The Ambetter Health brand served 5.5 million Marketplace members across 29 states as of December 31, 2025, with ICHRA plans offered in 6 states. The Other segment, comprising 3% of total external revenues, includes specialty pharmacy services through AcariaHealth, vision and dental services, clinical healthcare via Community Medical Group (CMG) and Denova Collaborative Health, and centralized services; notably, Centene signed a definitive agreement in December 2025 to divest the remaining Magellan Health businesses within this segment.

For the fiscal year ended December 31, 2025, Centene reported total revenues of $194,777 million, marking a 19% increase from $163,071 million in 2024. Premium and service revenues grew by 20% year-over-year to $174,581 million from $145,505 million. However, the company experienced a significant decline in profitability, reporting a net loss attributable to Centene Corporation of $(6,674) million, a substantial decrease from net earnings of $3,305 million in 2024. This translated to a diluted loss per share of $(13.53) in 2025, compared to diluted earnings per share of $6.31 in the prior year. The gross profit for 2025, calculated as premium and service revenues less medical costs and cost of services, was $14,209 million, resulting in a gross margin of 8.14%, a contraction from the prior year. The company recorded an operating loss of $(7,623) million, yielding an operating margin of -3.91%. Despite the net loss, Centene generated strong operating cash flows of $5,088 million in 2025, a significant improvement from $154 million in 2024. After accounting for capital expenditures of $767 million, free cash flow for 2025 was approximately $4,321 million. As of December 31, 2025, cash and cash equivalents stood at $17,888 million, while total debt was $17,401 million, resulting in a net cash position of $(487) million.

The year-over-year financial performance in 2025 was significantly impacted by several factors. Total revenues increased due to premium yield and membership growth in the PDP business, overall market expansion in the Marketplace, and rate increases in Medicaid, partially offset by lower Medicaid membership and reduced Marketplace estimated risk adjustment revenue. The Health Benefits Ratio (HBR) deteriorated to 91.9% in 2025 from 88.3% in 2024, primarily driven by lower Marketplace estimated risk adjustment revenue, increased Marketplace medical costs, program changes in the PDP business due to the Inflation Reduction Act (IRA), and higher medical costs in Medicaid, particularly from behavioral health, home health, and high-cost drugs. Conversely, the Selling, General and Administrative (SG&A) expense ratio improved to 7.4% in 2025 from 8.5% in 2024, reflecting continued cost discipline, leverage over higher revenues, and growth in the PDP business which operates at a lower SG&A ratio. Membership decreased by 967 thousand, or 3%, to 27.6 million, primarily due to Medicaid redeterminations, though Marketplace membership increased by 26% and Medicare PDP membership grew by 17%.

Significant operational developments in 2025 included a non-cash goodwill impairment charge of $6.7 billion recorded in the third quarter, alongside a $513 million impairment related to the pending divestiture of Magellan Health businesses. The company secured several Medicaid contract renewals and expansions in states such as Iowa, Mississippi, Florida, Kansas, Michigan, New Hampshire, and Texas, while concluding its New Mexico Medicaid contract in June 2024 and protesting reprocurement results in Texas and Georgia. In Medicare, Wellcare expanded its Medicare Advantage offerings into Iowa but discontinued plans in six other states, leading to a 10% decline in Medicare Advantage membership. The IRA's changes to Medicare Part D significantly increased premiums for PDPs due to a shift in cost-sharing responsibilities. In the Commercial segment, the Ambetter Health Marketplace product expanded into 60 new counties across 10 states, including Iowa, contributing to its 26% membership growth. The company also took corrective pricing actions for 2026 Marketplace rates in states covering 95% of its membership during the third quarter of 2025 to address higher projected morbidity.

While specific consolidated revenue, margin, or EPS guidance for the upcoming period is not explicitly provided within the filing, Centene's management emphasizes its commitment to successfully navigating industry changes and driving long-term growth. A key strategic growth initiative involves an enterprise-level focus on the D-SNP opportunity, aiming to enhance integrated care for the approximately 12 million dual-eligible beneficiaries nationwide. This strategy is supported by the company's overlapping Medicaid and Medicare Advantage footprints, positioning it well for CMS regulations that will require integrated care through D-SNPs for dually enrolled beneficiaries by 2030, with certain restrictions beginning in 2027. Furthermore, the company plans to expand its Individual Coverage Health Reimbursement Arrangement (ICHRA) offerings, with Ambetter Health Solutions operating plans designed to attract ICHRA membership in 13 states in 2026, up from 6 states in 2025, targeting the significant employer-sponsored insurance market.

In terms of segment and geographic expansion, the Medicaid segment anticipates new contracts, including Health Net Community Solutions providing managed dental health care services in Los Angeles and Sacramento counties in California starting January 2026, and SilverSummit Healthplan continuing Medicaid managed care services in Nevada, expanding into rural and frontier areas, also beginning January 2026. For Medicare, Wellcare will continue offering Medicare Advantage plans in 32 states and PDP products across all 50 states in 2026, with new Fully Integrated Dual Eligible Special Needs Plans (FIDE SNPs) commencing in Illinois and Ohio, and a Highly Integrated Dual Eligible Special Needs Plan (HIDE SNP) in Michigan, all in January 2026. The Commercial segment will see Ambetter Health offered in 29 states in 2026, with ICHRA plans expanding to 13 states. Planned capital allocation for 2026 includes approximately $800 million in capital expenditures, primarily for system enhancements and computer hardware and software. The company also has a substantial share repurchase program, with $1.8 billion remaining as of December 31, 2025, and an additional $1.0 billion authorized in February 2026, bringing the total available to $1.5 billion. Similarly, the senior note debt repurchase program had $513 million available as of December 31, 2025, increased by $1.0 billion in February 2026 to $1.484 billion, following a $29 million repurchase in January 2026. Management expects to receive net dividends of approximately $1.2 billion from its regulated subsidiaries in 2026.

However, the growth plan faces several key structural headwinds and execution risks flagged by management. The One Big Beautiful Bill Act (OBBBA), passed in July 2025, is expected to reduce Medicaid Expansion eligibility through work requirements, more frequent redeterminations, and cost-sharing, potentially increasing the overall morbidity of the Medicaid Expansion population starting in 2027. New York's Essentials Plan-5 is slated for termination by July 1, 2026, and the OBBBA also restricts payments to "prohibited entities" as of October 1, 2025, which could create access-to-care issues. In the Marketplace, the expiration of Enhanced Advance Premium Tax Credits (APTCs) at the end of 2025, coupled with the Marketplace Integrity and Affordability Final Rule and OBBBA restrictions on APTCs (e.g., reimbursement for mis-estimated income, prohibition for Special Enrollment Periods associated with income, both effective January 1, 2026), are anticipated to reduce 2026 Marketplace membership and increase the morbidity of the remaining population. For Medicare, the elimination of narrowed risk corridors for PDPs in 2026 and the draft 2027 Medicare rate announcement, which management believes is insufficient to reflect medical cost trends, pose profitability challenges. The Medicare Prescription Payment Plan (M3P) also introduces increased bad debt exposure and estimation uncertainty. Ongoing Medicaid reprocurement protests in Georgia and Texas, the conclusion of the Florida Children's Medical Services contract in September 2026, and the rebid process for Arizona's Long Term Care System (ALTCS) further introduce uncertainty regarding future Medicaid revenues and membership.

Centene operates within a complex and highly regulated environment, exposing it to a multitude of material risks spanning macroeconomic, competitive, regulatory, geopolitical, and operational domains. Macroeconomic risks include the potential for increased medical cost trends driven by inflation, interest rates, and volatility in financial markets, which can reduce the company's ability to accurately predict and control healthcare costs. Competitively, the company faces intense pressure from industry consolidation, new market entrants, and evolving broker distribution channels, which could limit its ability to increase market penetration, retain members and providers, or maintain pricing flexibility. Regulatory risks are pervasive, with potential rate cuts, insufficient rate changes, or payment delays from government payors, particularly in Medicaid and Medicare programs, posing significant threats. Changes to federal and state laws, including the Affordable Care Act (ACA), the Inflation Reduction Act (IRA), and the One Big Beautiful Bill Act (OBBBA), could alter eligibility requirements, reduce funding, or impose new operational burdens, such as the OBBBA's requirements for work or community engagement in Medicaid Expansion programs and the termination of New York's Essentials Plan-5 by July 1, 2026. The company's risk-adjustment payment systems are subject to variability and audits, potentially leading to retroactive adjustments and refunds of premiums to government customers, which could be significant. Furthermore, the Medicare Part D program faces unique risks from IRA changes, including increased risk exposure and potential bad debt from the Medicare Prescription Payment Plan (M3P). Operational risks include the failure to timely identify and mitigate medical cost trends, challenges in accurately pricing products or anticipating demand, the ineffectiveness of state-operated systems or subcontractors, and the submission of inaccurate or incomplete encounter data, which can lead to financial penalties. The company also highlights the risk of inability to maintain relationships with provider networks, the failure of third-party vendors to meet contractual obligations, and disruptions from integrating and managing information systems. Cybersecurity threats, including cyber-attacks and data security incidents, remain a material concern, although past incidents have not resulted in material financial loss or penalty to date. The company also faces the risk of goodwill and intangible asset impairment, as evidenced by the $6.7 billion non-cash goodwill impairment recorded in the third quarter of 2025, driven by market conditions and the OBBBA. Geopolitical risks, such as acts of war or aggression, and operational disruptions from disasters, climate-related incidents, or major epidemics, are also disclosed as potential threats to business continuity and financial performance. Additionally, the company is involved in costly and time-consuming litigation and regulatory proceedings, including a federal securities class action and related derivative lawsuits filed in July 2025, which could divert management attention and result in substantial damages or penalties.

Management's message to shareholders conveys a tone of resilience and strategic focus amidst a dynamic and challenging healthcare landscape, emphasizing the company's mission to transform community health. The leadership team underscores Centene's commitment to its core identity as the largest managed care company for underserved populations, highlighting its local approach, partnership mindset, and the strength of its 61,100 team members in delivering high-quality, culturally sensitive healthcare. While specific consolidated financial guidance for the upcoming fiscal year is not provided in the filing, management articulates a clear forward-looking perspective, stating the company's belief in its capacity and capability to successfully navigate industry changes through program and bid design, product placement, and other strategic factors.

The two or three strategic priorities emphasized by management for the period ahead include a strong focus on the Dual Eligible Special Needs Plan (D-SNP) opportunity to drive long-term growth, leveraging the company's overlapping Medicaid and Medicare Advantage footprints to enhance integrated care for dual-eligible members. A second key priority involves maintaining the affordability of healthcare for government partners and members, which entails addressing medical cost trends through new clinical initiatives, thoughtful network design, and continuous rigor in combating fraud, waste, and abuse. Finally, management is committed to the ongoing use of data and analytics, including artificial intelligence and machine learning, to improve the provider and member experience, personalize care, and ultimately drive better health outcomes, while also ensuring responsible and ethical deployment of these technologies.